Aashima Arora
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aashima Arora has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Vanita Suri
Department of Obstetrics and Gynaecology, Postgraduate Institute of Medical Education and Research (PGIMER)
6 shared publicationsVanita Jain
Department of Obstetrics and Gynaecology, Postgraduate Institute of Medical Education and Research (PGIMER)
5 shared publicationsPooja Sikka
Department of Obstetrics and Gynaecology, Postgraduate Institute of Medical Education and Research (PGIMER)
4 shared publications- Arihant Jain
Department of Clinical Hematology and Medical Oncology, PGIMER, Chandigarh, India
3 shared publications - Pradip Kumar Saha
Department of Obstetrics and Gynaecology, Postgraduate Institute of Medical Education and Research (PGIMER) Chandigarh, 160012, India
3 shared publications Rashmi Bagga
Department of Obstetrics and Gynaecology, Postgraduate Institute of Medical Education and Research (PGIMER) Chandigarh, 160012, India
3 shared publications
Latest Publications
- 28 October 2026
- Published by Elsevier in Transfusion and Apheresis Science
Blood ordering in obstetric haemorrhage: Do we need one rule for all conditions?
- 28 October 2026
- Published by Elsevier in Transfusion and Apheresis Science
Blood ordering in obstetric haemorrhage: Do we need one rule for all conditions?
- 17 March 2026
- Published by Taylor & Francis in Hospital Topics
- p. 1-10
Identifying At-Risk Population for Varicella Zoster and Rubella Virus Infection Among Healthcare Workers Providing Care to Antenatal Women and Newborns: A Serosurvey from a Resource Constrained Setting
A study was conducted to assess seroprevalence against varicella zoster virus(VZV) and rubella virus among health care workers providing care to antenatal patients and newborn babies. A cross-sectional study enrolled healthcare workers(HCWs) working in the departments of Obstetrics and Gynecology and Pediatrics, collecting sociodemographic details along with a request for 3 mL blood samples. Serum titers of IgG antibodies against VZV and rubella were measured by ELISA(Enzyme-Linked Immunosorbent Assay). Two-hundred HCW participants were enrolled in the study. The average age of the study participants was 31.25 ± 8 years. Among 200 HCW participants 163(81.5%) were positive, 28(14%) negative, and 01(0.5%) participant had a borderline status for VZV. Similarly, 179(89.5%) were positive, 19(9.5%) negative, and 02(1%) participants were of borderline status for Rubella. Study observed a statistically significant impact of past active VZV infection, as indicated by 92.1% antibody positivity among HCWs(p = 0.000012). However, serological status against VZV and rubella were not observed to be associated with age(p = 0.18 and 0.28), gender(p = 0.75 & 0.28), profession type(p = 0.39 and 0.74), professional experience in years(p = 0.43 and 0.9), marital status(p = 0.09 and 0.6), parity(p = 0.25 and 0.9), vaccination in the past(p = 0.12), awareness about Infection during pregnancy(0.5 and 0.57) respectively. Present study offered free vaccination to seronegative healthcare workers(HCWs) and also collected information on the reasons for their refusal to get vaccinated. Pre-employment vaccination and infection history are essential to prevent complications for oneself and to contain the spread of VZV and rubella infections in hospitals that provide care to pregnant women and their newborns.
- 17 March 2026
- Published by Taylor & Francis in Hospital Topics
- p. 1-10
Identifying At-Risk Population for Varicella Zoster and Rubella Virus Infection Among Healthcare Workers Providing Care to Antenatal Women and Newborns: A Serosurvey from a Resource Constrained Setting
A study was conducted to assess seroprevalence against varicella zoster virus(VZV) and rubella virus among health care workers providing care to antenatal patients and newborn babies. A cross-sectional study enrolled healthcare workers(HCWs) working in the departments of Obstetrics and Gynecology and Pediatrics, collecting sociodemographic details along with a request for 3 mL blood samples. Serum titers of IgG antibodies against VZV and rubella were measured by ELISA(Enzyme-Linked Immunosorbent Assay). Two-hundred HCW participants were enrolled in the study. The average age of the study participants was 31.25 ± 8 years. Among 200 HCW participants 163(81.5%) were positive, 28(14%) negative, and 01(0.5%) participant had a borderline status for VZV. Similarly, 179(89.5%) were positive, 19(9.5%) negative, and 02(1%) participants were of borderline status for Rubella. Study observed a statistically significant impact of past active VZV infection, as indicated by 92.1% antibody positivity among HCWs(p = 0.000012). However, serological status against VZV and rubella were not observed to be associated with age(p = 0.18 and 0.28), gender(p = 0.75 & 0.28), profession type(p = 0.39 and 0.74), professional experience in years(p = 0.43 and 0.9), marital status(p = 0.09 and 0.6), parity(p = 0.25 and 0.9), vaccination in the past(p = 0.12), awareness about Infection during pregnancy(0.5 and 0.57) respectively. Present study offered free vaccination to seronegative healthcare workers(HCWs) and also collected information on the reasons for their refusal to get vaccinated. Pre-employment vaccination and infection history are essential to prevent complications for oneself and to contain the spread of VZV and rubella infections in hospitals that provide care to pregnant women and their newborns.
- Open Access
- 29 October 2025
- Published by Medip Academy in International Journal of Reproduction, Contraception, Obstetrics and Gynecology
- Vol. 14 (11) , 4016-4018
Coexistence of acute fatty liver of pregnancy, gestational diabetes insipidus, and preeclampsia leading to severe hypernatremia and perinatal mortality: a case report
Acute fatty liver of pregnancy (AFLP) and gestational diabetes insipidus (GDI) are rare but life-threatening obstetric complications. AFLP is linked to hepatic dysfunction, which can impair the breakdown of placental vasopressinase, leading to GDI and eventually hypernatremia. The coexistence of AFLP with GDI can be further worsened by placental dysfunction associated with preeclampsia, due to the disruption of the placental barrier that allows fetal vasopressin to enter the maternal circulation. This rare confluence of AFLP, GDI, and preeclampsia is scarcely reported and presents significant diagnostic and management challenges. We report a 25-year-old G2P1 woman, at 36 weeks of pregnancy, presenting with fever, jaundice, altered mentation, and hypertension. Laboratory tests showed hypernatremia (195 mEq/l), low urine osmolality, and abnormal kidney and liver function tests. Swansea criteria confirmed AFLP. Sodium was gradually corrected at a rate of 6-8 mEq/l per day, and vaginal delivery was planned. A live baby weighing 2.08 kg was delivered but died from respiratory failure on day two. Maternal recovery was complete by day 11 postpartum. This case highlights the interaction between AFLP, preeclampsia, and GDI. It emphasizes the importance of careful sodium correction and increased suspicion of vasopressinase dysfunction in cases of unexplained hypernatremia.
- 29 October 2025
- Published by Medip Academy in International Journal of Reproduction, Contraception, Obstetrics and Gynecology
- Vol. 14 (11) , 4016-4018
Open AccessCoexistence of acute fatty liver of pregnancy, gestational diabetes insipidus, and preeclampsia leading to severe hypernatremia and perinatal mortality: a case report
Acute fatty liver of pregnancy (AFLP) and gestational diabetes insipidus (GDI) are rare but life-threatening obstetric complications. AFLP is linked to hepatic dysfunction, which can impair the breakdown of placental vasopressinase, leading to GDI and eventually hypernatremia. The coexistence of AFLP with GDI can be further worsened by placental dysfunction associated with preeclampsia, due to the disruption of the placental barrier that allows fetal vasopressin to enter the maternal circulation. This rare confluence of AFLP, GDI, and preeclampsia is scarcely reported and presents significant diagnostic and management challenges. We report a 25-year-old G2P1 woman, at 36 weeks of pregnancy, presenting with fever, jaundice, altered mentation, and hypertension. Laboratory tests showed hypernatremia (195 mEq/l), low urine osmolality, and abnormal kidney and liver function tests. Swansea criteria confirmed AFLP. Sodium was gradually corrected at a rate of 6-8 mEq/l per day, and vaginal delivery was planned. A live baby weighing 2.08 kg was delivered but died from respiratory failure on day two. Maternal recovery was complete by day 11 postpartum. This case highlights the interaction between AFLP, preeclampsia, and GDI. It emphasizes the importance of careful sodium correction and increased suspicion of vasopressinase dysfunction in cases of unexplained hypernatremia.
- 7 December 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (4) , 947-950
Impact of Dasatinib on Female Reproductive Health in Philadelphia-Positive Leukemia Patients
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML), with patients now achieving life expectancy comparable to the general population. Despite the contraindication of TKIs during the first trimester of pregnancy, their effects on female reproductive health remain underexplored. This pilot case–control study evaluated the impact of Dasatinib on the female reproductive system in 25 women with CML or Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL), compared to 25 age-matched controls. Clinical histories, gynecological examinations, transvaginal ultrasonography, and serum Anti-Müllerian hormone (AMH) assessments were performed. There was no significant differences in menstrual cycle characteristics between patients and controls, although 12% of patients experienced shorter cycles and 8% reported heavier menstrual flow after initiating Dasatinib. Notably, patients on Dasatinib had significantly lower serum AMH levels (p < 0.005) and a higher incidence of low antral follicle count (AFC < 5 mm). Abnormal cervical cytology was observed in one patient, and two tested positive for HPV DNA. Dasatinib may subtly but significantly affect ovarian reserve and cervical health. Larger studies are needed to clarify these reproductive effects and inform clinical management in women receiving Dasatinib therapy.
- 7 December 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (4) , 947-950
Impact of Dasatinib on Female Reproductive Health in Philadelphia-Positive Leukemia Patients
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML), with patients now achieving life expectancy comparable to the general population. Despite the contraindication of TKIs during the first trimester of pregnancy, their effects on female reproductive health remain underexplored. This pilot case–control study evaluated the impact of Dasatinib on the female reproductive system in 25 women with CML or Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL), compared to 25 age-matched controls. Clinical histories, gynecological examinations, transvaginal ultrasonography, and serum Anti-Müllerian hormone (AMH) assessments were performed. There was no significant differences in menstrual cycle characteristics between patients and controls, although 12% of patients experienced shorter cycles and 8% reported heavier menstrual flow after initiating Dasatinib. Notably, patients on Dasatinib had significantly lower serum AMH levels (p < 0.005) and a higher incidence of low antral follicle count (AFC < 5 mm). Abnormal cervical cytology was observed in one patient, and two tested positive for HPV DNA. Dasatinib may subtly but significantly affect ovarian reserve and cervical health. Larger studies are needed to clarify these reproductive effects and inform clinical management in women receiving Dasatinib therapy.
- 27 August 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (2) , 327-332
Effect of Imatinib Mesylate on the Ovarian Reserves of Female Patients with Chronic Myeloid Leukaemia
Purpose: Imatinib mesylate (IM) has transformed the treatment of chronic myeloid leukaemia (CML). The improved life expectancy of CML patients has led to increased attention to the adverse effects of the drug. There are conflicting reports of the impact of IM on the female reproductive system. A few studies suggested that IM may reduce ovarian reserve and cause menstrual irregularities in female patients. We systematically looked at the effect of IM on the female reproductive system in a case-control study. Methodology: The study was conducted in the outpatient clinics of the Department of Obstetrics and Gynaecology and the Haematology Clinic. We enrolled 44 patients with CML chronic phase (CML-CP) who had been taking IM for at least one year and 24 patients who had been newly diagnosed with CML CP but had not yet started treatment with IM. CML CP was diagnosed through bone marrow examination and the detection of BCR-ABL transcripts via polymerase chain reaction (PCR). We administered a structured questionnaire to obtain demographic information, menstrual and sexual history, and age at menopause from all patients who had not yet reached menopause at the time of recruitment. We evaluated the effects of IM on menstrual pattern and ovarian reserve using quantitative and qualitative measures, including menstrual cycle characteristics, antral follicle count (AFC), and Anti-Mullerian hormone (AMH) levels in both groups of patients. A transvaginal ultrasound was performed between days 2–5 of the menstrual cycle to determine AFC. AMH levels were tested in the serum of menstruating patients among both cases (n = 30) and controls (n = 19). These variables were compared between both groups to determine the association between IM use and ovarian reserve. Results: The median age of the cases was 40.5 years (range: 22.0–71.0), while the control population had a median age of 35.5 years (range: 22.0–60.0). The median duration of IM therapy was 2.5 years, with a range of 1–15 years. After excluding patients who had already reached menopause at the time of recruitment, there was no significant difference in AMH levels (3.00 ± 5.43 ng/mL in cases versus 4.38 ± 4.69 ng/mL in controls; p = 0.154) or AFC (4.97 ± 3.31 in cases versus 6.16 ± 3.50 in controls; p = 0.219). Similarly, the two groups had no significant difference in menstrual cycle characteristics. However, the age at menopause was significantly lower in patients taking IM for at least one year (except for three women who had already reached menopause before starting imatinib), compared to the control group (41.00 ± 3.46 years versus 47.80 ± 2.49 years, p = 0.006). Conclusion: The study found no significant differences in ovarian reserve parameters, as measured by menstrual cycle characteristics, AMH levels, and antral follicle count, between CML patients receiving IM therapy and newly diagnosed patients who had not yet started treatment. However, our findings highlight the potential risk of early iatrogenic menopause in patients receiving IM therapy, indicating the need for further investigation through larger studies.
- 27 August 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (2) , 327-332
Effect of Imatinib Mesylate on the Ovarian Reserves of Female Patients with Chronic Myeloid Leukaemia
Purpose: Imatinib mesylate (IM) has transformed the treatment of chronic myeloid leukaemia (CML). The improved life expectancy of CML patients has led to increased attention to the adverse effects of the drug. There are conflicting reports of the impact of IM on the female reproductive system. A few studies suggested that IM may reduce ovarian reserve and cause menstrual irregularities in female patients. We systematically looked at the effect of IM on the female reproductive system in a case-control study. Methodology: The study was conducted in the outpatient clinics of the Department of Obstetrics and Gynaecology and the Haematology Clinic. We enrolled 44 patients with CML chronic phase (CML-CP) who had been taking IM for at least one year and 24 patients who had been newly diagnosed with CML CP but had not yet started treatment with IM. CML CP was diagnosed through bone marrow examination and the detection of BCR-ABL transcripts via polymerase chain reaction (PCR). We administered a structured questionnaire to obtain demographic information, menstrual and sexual history, and age at menopause from all patients who had not yet reached menopause at the time of recruitment. We evaluated the effects of IM on menstrual pattern and ovarian reserve using quantitative and qualitative measures, including menstrual cycle characteristics, antral follicle count (AFC), and Anti-Mullerian hormone (AMH) levels in both groups of patients. A transvaginal ultrasound was performed between days 2–5 of the menstrual cycle to determine AFC. AMH levels were tested in the serum of menstruating patients among both cases (n = 30) and controls (n = 19). These variables were compared between both groups to determine the association between IM use and ovarian reserve. Results: The median age of the cases was 40.5 years (range: 22.0–71.0), while the control population had a median age of 35.5 years (range: 22.0–60.0). The median duration of IM therapy was 2.5 years, with a range of 1–15 years. After excluding patients who had already reached menopause at the time of recruitment, there was no significant difference in AMH levels (3.00 ± 5.43 ng/mL in cases versus 4.38 ± 4.69 ng/mL in controls; p = 0.154) or AFC (4.97 ± 3.31 in cases versus 6.16 ± 3.50 in controls; p = 0.219). Similarly, the two groups had no significant difference in menstrual cycle characteristics. However, the age at menopause was significantly lower in patients taking IM for at least one year (except for three women who had already reached menopause before starting imatinib), compared to the control group (41.00 ± 3.46 years versus 47.80 ± 2.49 years, p = 0.006). Conclusion: The study found no significant differences in ovarian reserve parameters, as measured by menstrual cycle characteristics, AMH levels, and antral follicle count, between CML patients receiving IM therapy and newly diagnosed patients who had not yet started treatment. However, our findings highlight the potential risk of early iatrogenic menopause in patients receiving IM therapy, indicating the need for further investigation through larger studies.
- 8 November 2023
- Published by Taylor & Francis in Hospital Topics
- Vol. 103 (3) , 155-163
Naturalistic Evaluation of ERAS Bundle Implementation Feasibility in Elective Cesarean Deliveries of Tertiary Care Hospital in a Low-Middle-Income Country
The present study assessed whether applying enhanced recovery after surgery (ERAS) guidelines for cesarean delivery is feasible in the tertiary care setting with an add-on objective to identify barriers to successful implementation. The cross-sectional study included women undergoing elective CS and willing to participate. The study attempted to understand barriers to ERAS implementation through timely interviewing study participants. Sixty-two patients participated in the study. Antenatal and fetal complications were observed in 39(63%) and 32(51%) participants. The study observed that at least 80% of the proposed components could be applied to 71% of the study population. All 15 components could be applied to 7(11.2%) patients, and at least 50% could be applied to 58(94%) patients. The least applied component was minimizing starvation by taking clear liquids until 2 hrs before surgery in 26(42%) patients due to waiting hours outside the operation-theater (OT). When fitness-for-discharge was assessed against the percent components of ERAS implemented, the area under the curve (AUC) value was 0.75, with a specificity value of 95.65% and a positive predictive value of 94.12%. In the postoperative ERAS bundle, fitness-for-discharge on day-two was statistically associated with early and frequent breastfeeding (p = 0.000) and prevention of intra-op hypotension (p = 0.03). In conclusion, the primary barriers to implementing ERAS were resource limitations in the form of single functional OT and limited doctors.
- 8 November 2023
- Published by Taylor & Francis in Hospital Topics
- Vol. 103 (3) , 155-163
Naturalistic Evaluation of ERAS Bundle Implementation Feasibility in Elective Cesarean Deliveries of Tertiary Care Hospital in a Low-Middle-Income Country
The present study assessed whether applying enhanced recovery after surgery (ERAS) guidelines for cesarean delivery is feasible in the tertiary care setting with an add-on objective to identify barriers to successful implementation. The cross-sectional study included women undergoing elective CS and willing to participate. The study attempted to understand barriers to ERAS implementation through timely interviewing study participants. Sixty-two patients participated in the study. Antenatal and fetal complications were observed in 39(63%) and 32(51%) participants. The study observed that at least 80% of the proposed components could be applied to 71% of the study population. All 15 components could be applied to 7(11.2%) patients, and at least 50% could be applied to 58(94%) patients. The least applied component was minimizing starvation by taking clear liquids until 2 hrs before surgery in 26(42%) patients due to waiting hours outside the operation-theater (OT). When fitness-for-discharge was assessed against the percent components of ERAS implemented, the area under the curve (AUC) value was 0.75, with a specificity value of 95.65% and a positive predictive value of 94.12%. In the postoperative ERAS bundle, fitness-for-discharge on day-two was statistically associated with early and frequent breastfeeding (p = 0.000) and prevention of intra-op hypotension (p = 0.03). In conclusion, the primary barriers to implementing ERAS were resource limitations in the form of single functional OT and limited doctors.
- 24 March 2022
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 42 (6) , 2535-2539
Developing locoregional evidence through comparison of WHO and national maternal near miss criteria: a cross sectional study experience from low resource setting
India, a prototype developing nation, accounts for the second-highest maternal mortality in the world. India’s recent maternal mortality (MMR) figures were still twice the global targets of sustain...
- 24 March 2022
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 42 (6) , 2535-2539
Developing locoregional evidence through comparison of WHO and national maternal near miss criteria: a cross sectional study experience from low resource setting
India, a prototype developing nation, accounts for the second-highest maternal mortality in the world. India’s recent maternal mortality (MMR) figures were still twice the global targets of sustain...